Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | $-201M | $-201M | $-167M | -166.4% | 55.3% | 2.7% |
| 2024 | $3M | $-196M | $-196M | $-130M | -127.9% | - | -1.1% |
| 2023 | $0M | $-187M | $-198M | $-174M | -148.9% | - | 62.6% |
| 2022 | $0M | $-114M | $-122M | $-148M | -38.5% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 2.98 | 4.63 |
| Operating Revenue | - | 0 | 0 | 2.98 | 4.63 |
| Operating Expense | - | 116.54 | 191.29 | 205.45 | 212.98 |
| Research And Development | - | 86.72 | 147.90 | 155.29 | 160.64 |
| Selling General And Administration | - | 29.82 | 43.39 | 50.16 | 52.35 |
| Total Expenses | - | 116.54 | 191.29 | 205.45 | 212.98 |
| Operating Income | - | -116.54 | -191.29 | -202.47 | -208.35 |
| Total Operating Income As Reported | - | -116.54 | -204.79 | -202.47 | -208.35 |
| EBITDA | - | -114.32 | -186.64 | -196.34 | -201.03 |
| Normalized EBITDA | - | -106.19 | -170.76 | -195.85 | -201.46 |
| EBIT | - | -116.54 | -191.29 | -202.47 | -208.35 |
| Interest Income | - | - | 2.81 | 3.52 | 4.15 |
| Net Interest Income | - | - | 2.81 | 3.52 | 4.15 |
| Other Non Operating Income Expenses | - | 1.90 | 0.27 | 0.04 | 0.15 |
| Other Income Expense | - | -6.22 | -9.93 | 3.06 | 3.06 |
| Interest Income Non Operating | - | - | 2.81 | 3.52 | 4.15 |
| Net Non Operating Interest Income Expense | - | - | 2.81 | 3.52 | 4.15 |
| Pretax Income | - | -122.77 | -198.41 | -195.88 | -201.14 |
| Tax Provision | -0.49 | -0.95 | -0.28 | 0 | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.06 | -0.02 | 0 | 0 |
| Net Income Continuous Operations | - | -121.82 | -198.13 | -195.88 | -201.14 |
| Net Income From Continuing And Discontinued Operation | - | -121.82 | -198.13 | -195.88 | -201.14 |
| Net Income From Continuing Operation Net Minority Interest | - | -121.82 | -198.13 | -195.88 | -201.14 |
| Net Income | - | -121.82 | -198.13 | -195.88 | -201.14 |
| Net Income Common Stockholders | - | -142.01 | -198.13 | -195.88 | -201.14 |
| Net Income Including Noncontrolling Interests | - | -121.82 | -198.13 | -195.88 | -201.14 |
| Normalized Income | - | -113.75 | -182.27 | -195.40 | -201.57 |
| Diluted NI Availto Com Stockholders | - | -142.01 | -198.13 | -195.88 | -201.14 |
| Basic Average Shares | - | 33.89 | 90.97 | 118.60 | 148.76 |
| Diluted Average Shares | - | 33.89 | 90.97 | 118.60 | 148.76 |
| Reconciled Depreciation | - | 2.22 | 4.65 | 6.13 | 7.32 |
| Total Unusual Items | - | -8.13 | -15.88 | -0.48 | 0.43 |
| Total Unusual Items Excluding Goodwill | - | -8.13 | -15.88 | -0.48 | 0.43 |
| Preferred Stock Dividends | 17.28 | 20.19 | - | - | - |
| Special Income Charges | - | 0 | -13.50 | 0 | - |
| Other Special Charges | - | - | 13.50 | - | - |
| Gain On Sale Of Security | - | -8.13 | -2.38 | -0.48 | 0.43 |
| General And Administrative Expense | - | 29.82 | 43.39 | 50.16 | 52.35 |
| Other Gand A | - | 18.73 | 26.31 | 23.59 | 29.32 |
| Salaries And Wages | - | 11.09 | 17.08 | 26.57 | 23.03 |
| Otherunder Preferred Stock Dividend | 1.47 | 0 | - | - | - |
| Securities Amortization | - | - | -5.68 | -3.51 | -2.48 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Prime Medicine, Inc.this co. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Zevra Therapeutics, Inc. | ZVRA | $660M | 7.93 | 4.27 | 53.8% | 6.70 |
| SI-BONE, Inc. | SIBN | $660M | - | 3.72 | -10.6% | - |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Castle Biosciences, Inc. | CSTL | $655M |
| - |
| - |
| - |
| - |
| -27.12 |
| 1.39 |
| -5.1% |
| 50.72 |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Beta Bionics, Inc. | BBNX | $619M | -8.46 | 2.15 | -25.5% | -8.64 |
| Gyre Therapeutics, Inc. | GYRE | $601M | 119.48 | 5.66 | 4.7% | 40.29 |
| Phreesia, Inc. | PHR | $599M | 259.74 | 1.78 | 0.7% | 21.30 |
| Peer Median | - | -3.88 | 2.93 | -7.9% | 14.00 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Jun has averaged the highest return (+24.8%); Mar the lowest (-22.4%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +9.8%Positive MonthJan 2026: +9.80% | +21.3%Positive MonthFeb 2026: +21.26% | -24.7%Negative MonthMar 2026: -24.68% | +1.9%Neutral MonthApr 2026: +1.87% | +0.1%Neutral MonthMay 2026: +0.14% | +3.9%Positive MonthJun 2026: +3.94% | -20.9%Negative MonthJul 2026: -20.87% | +21.2%*Positive MonthAug 2026: +21.23% | — | — | — | — |
| 2025 | -4.1%Negative MonthJan 2025: -4.11% | -10.0%Negative MonthFeb 2025: -10.00% | -21.0%Negative MonthMar 2025: -21.03% | -13.1%Negative MonthApr 2025: -13.07% | -31.8%Negative MonthMay 2025: -31.79% | +109.3%Positive MonthJun 2025: +109.32% | +51.4%Positive MonthJul 2025: +51.42% | -13.4%Negative MonthAug 2025: -13.37% | +71.0%Positive MonthSep 2025: +70.99% | -10.8%Negative MonthOct 2025: -10.83% | -22.7%Negative MonthNov 2025: -22.67% | -9.2%Negative MonthDec 2025: -9.16% |
| 2024 | -28.3%Negative MonthJan 2024: -28.33% | +35.9%Positive MonthFeb 2024: +35.91% | -18.9%Negative MonthMar 2024: -18.89% | -29.7%Negative MonthApr 2024: -29.71% | +31.7%Positive MonthMay 2024: +31.71% | -20.7%Negative MonthJun 2024: -20.68% | +9.1%Positive MonthJul 2024: +9.14% | -23.7%Negative MonthAug 2024: -23.71% | -9.6%Negative MonthSep 2024: -9.58% | +0.3%Neutral MonthOct 2024: +0.26% | -15.2%Negative MonthNov 2024: -15.21% | -11.2%Negative MonthDec 2024: -11.25% |
| 2023 | -5.4%Negative MonthJan 2023: -5.38% | -6.5%Negative MonthFeb 2023: -6.54% | -25.1%Negative MonthMar 2023: -25.14% | +12.0%Positive MonthApr 2023: +11.95% | -0.4%Neutral MonthMay 2023: -0.36% | +6.8%Positive MonthJun 2023: +6.78% | +2.9%Positive MonthJul 2023: +2.87% | -12.1%Negative MonthAug 2023: -12.14% | -27.9%Negative MonthSep 2023: -27.95% | -32.0%Negative MonthOct 2023: -31.97% | +11.9%Positive MonthNov 2023: +11.86% | +22.0%Positive MonthDec 2023: +22.04% |
| 2022 | — | — | — | — | — | — | — | — | — | — | -8.7%Negative MonthNov 2022: -8.66% | +8.1%Positive MonthDec 2022: +8.09% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 5 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
